Archives
-
METTL14, SMN and m6A: Evidence and Limits
2026-10-06
This overview examines how one 2025 study connects arginine methylation, SMN, METTL14 and m6A RNA regulation. It separates reported findings from interpretation and explains the study’s evidentiary strength, biological scope and limitations.
-
Inhaled RNA Reprograms the Lung Cancer Microenvironment
2026-10-05
A 2025 Nature Communications study reports an inhalable lipid nanoparticle strategy that combines anti-DDR1 mRNA with PD-L1-targeting siRNA to address both collagen-mediated immune exclusion and tumor immunosuppression in lung cancer models. The findings support a preclinical framework for locally remodeling the tumor microenvironment, while leaving questions about human pulmonary delivery, durability, and safety unresolved.
-
ICAA, RIP3, and Cardiac Hypertrophy
2026-10-05
A 2026 Cellular Signalling study identifies isochlorogenic acid A as a regulator of RIP3-driven cardiac hypertrophy and links this effect to suppression of CaMKII signaling. The findings broaden mechanistic understanding of angiotensin II-associated remodeling, while remaining preclinical and requiring validation beyond the reported cell and animal models.
-
8-Chloroadenosine and the RNA Stability Frontier
2026-10-04
A source-grounded perspective on how 8-Chloroadenosine can help translational researchers distinguish transcriptional control from RNA stability in lncRNA-driven cancer biology, using the RP3-340N1.2–IL-6–ZC3H12A axis as a mechanistic case study.
-
GTP Solution: Reading the p21 mRNA-LNP Evidence
2026-10-03
GTP Solution is more than a nucleotide input for in vitro transcription: its scientific value depends on how reagent quality, mRNA biology, delivery, and evidence strength are connected. This article interprets the p21 mRNA-LNP bladder cancer study while separating product specifications from demonstrated therapeutic outcomes.
-
Pseudo-UTP for mRNA Synthesis: Workflow & Uses
2026-10-02
Pseudo-UTP enables controlled pseudouridine incorporation for RNA stability enhancement, translation studies, and immune-response profiling. This practical guide connects mRNA vaccine development and gene therapy RNA modification with an optimized in vitro transcription workflow, assay controls, and troubleshooting strategies.
-
TRIM66 and Monogenic Olfactory Receptor Expression
2026-10-01
The reference study identifies TRIM66 as an epigenetic repressor that helps mature olfactory sensory neurons silence surplus olfactory receptor genes and preserve monogenic receptor expression. By connecting receptor-gene regulation with enhancer repression, neural activity, and innate olfactory behavior, the work clarifies how olfactory neurons transition from an initially permissive state to the one-neuron–one-receptor state.
-
Antimycin A4: Dual-Pathway Metabolism Tool
2026-10-01
Antimycin A4 is an ATP-citrate lyase inhibitor and mitochondrial respiratory-chain inhibitor. Its dual activity makes it useful for controlled studies of lipid synthesis, electron transport, and eukaryotic energy metabolism.
-
Broad-Spectrum Bivalent mRNA Vaccine: Preclinical Evidence
2026-09-30
The reference study evaluates RQ3025, a bivalent mRNA vaccine designed around shared SARS-CoV-2 spike mutations, rather than a single circulating strain. Across mouse, hamster, and rat models, the vaccine produced broad neutralizing responses, variant protection, a Th1-biased cellular response, and no observed histopathological abnormalities at the tested high dose, while remaining limited to preclinical evidence.
-
IMP for RNA Modification LC-MS Workflows
2026-09-30
Use IMP to strengthen peak assignment and quantitative control in proximity-resolved RNA modification studies. This workflow connects APEX2 labeling, stress or DNA-damage perturbations, nucleoside LC-MS, and orthogonal localization assays while keeping analyte identity and sampling artifacts in view.
-
IMP in Spatial RNA Modification Workflows
2026-09-29
IMP provides a chemically distinct reference point for RNA and nucleotide LC-MS workflows. This guide explains how IMP relates to APEX-RNA-MS, when it is appropriate for assay development, and why spatial sampling must be separated from molecular identification.
-
Anti-ROR1 Antibody: From Mechanism to Translation
2026-09-29
A translational framework for using Zilovertamab to test ROR1 biology across oncology and toxin-induced liver injury models while separating established evidence from exploratory hypotheses.
-
NAT10–ac4C Control of Mouse Oocyte Maturation
2026-09-28
Xiang et al. identify NAT10-mediated N4-acetylcytidine (ac4C) as a post-transcriptional regulator of mouse oocyte maturation in vitro. NAT10 knockdown reduced ac4C modification and impaired first polar body extrusion, while transcriptomic and RNA pulldown analyses implicated chromatin-associated pathways and TBL3 as a potential ac4C-binding protein.
-
MGMT Inhibition: From Mechanism to Translation
2026-09-28
MGMT can determine whether alkylation damage becomes a therapeutic liability or a repairable lesion. This article connects recent findings on AP-2α and temozolomide resistance with practical strategies for studying O6-Benzylguanine as a mechanistic MGMT inhibitor—while distinguishing transcriptional suppression from direct enzyme inactivation.
-
8-Chloroadenosine in Viability Assay Design
2026-09-27
A practical guide to using 8-Chloroadenosine (SKU B7667) in cell viability, proliferation, and RNA metabolism experiments. It connects product specifications with assay controls and published RNA-regulation research while distinguishing workflow recommendations from evidence-backed findings.